NNVC — NANOVIRICIDES, INC.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1379006 ·
Last close
$1.44
Market Cap
$36.76M
52W High
$2.23
52W Low
$0.85
ADV30
505,313
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,030,218 | -1,989,333 | 10,219,004 | 3,213,256 | 1,065,407 |
| Dec 2025 | 0 | — | -2,233,174 | -2,220,719 | 12,267,640 | 5,150,580 | 1,195,925 |
| Sep 2025 | 0 | — | -1,796,685 | -1,785,058 | 8,357,080 | 1,125,711 | 1,182,386 |
| Jun 2025 | 0 | — | -2,115,603 | -2,095,881 | 8,824,085 | 1,558,564 | 1,306,519 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,276,000
Investing CF
$-94,516
Financing CF
$8,041,182
CapEx
$-94,517
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.44
As of
2026-09-06
Balance + Analyst (yfinance extras)
Retained Earnings
$-154,836,971
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-8,102,618
Pretax Income TTM
$-8,090,991
Interest Exp TTM
$0
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 0 | -9,591,645 | -9,466,966 | 8,824,085 | 1,306,519 | 7,517,566 | -8,478,679 |
| Jun 2024 | 0 | -8,516,111 | -8,294,146 | 12,822,853 | 1,358,776 | 11,464,077 | -6,315,507 |
| Jun 2023 | 0 | -8,943,468 | -8,588,573 | 16,899,880 | 2,034,250 | 14,865,630 | -5,670,051 |
| Jun 2022 | 0 | -8,113,599 | -8,106,863 | 23,494,862 | 412,837 | 23,082,025 | -5,891,254 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.35
Max Pain — expiry 2027-03-19
max pain strike: $2.50 · spot: $1.52 · call oi: 2,808 · put oi: 19
Expected Move to 2027-03-19:
±$1.75
(114.75%) —
implied range
$-0.23 –
$3.27
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc. | $36.74M | $1.62 | — |
| FLNA | FILANA THERAPEUTICS, INC. | $36.23M | $0.75 | — |
| BCTX | BriaCell Therapeutics Corp. | $37.58M | $4.32 | — |
| ATNM | Actinium Pharmaceuticals, Inc. | $37.73M | $1.20 | — |
| PYRGF | PyroGenesis Canada Inc. | $35.77M | $0.16 | — |
News headlines (Yahoo Finance, 1h cache)
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
2026-09-23 12:30 · Yahoo
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
2026-09-08 12:30 · Yahoo
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measle
2026-08-31 12:30 · Yahoo
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
2026-08-10 12:30 · Yahoo
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
2026-07-13 13:27 · Yahoo
REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan
2026-06-25 13:00 · Yahoo
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
2026-06-22 13:30 · Yahoo
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Feat
2026-06-08 12:30 · Yahoo
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
2026-08-18 12:30 · Yahoo
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockI
2026-07-08 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.